Related Experiment Videos
A two-component expression system that responds to inflammatory stimuli in vivo
A W Varley1, S M Geiszler, R B Gaynor
1Molecular Host Defense Laboratory, UT Southwestern Medical Center, Dallas 75235-9113, USA.
Nature Biotechnology
|October 23, 1997
Summary
Gene therapy offers a solution to managing inflammatory diseases by creating inflammation-inducible systems. This approach links recombinant protein production to inflammatory signals, balancing therapeutic benefits with reduced immunosuppression risks.
Area of Science:
- Biotechnology
- Molecular Biology
- Immunology
Background:
- Managing inflammatory diseases presents a therapeutic challenge, requiring a balance between reducing inflammation and avoiding chronic immunosuppression.
- Gene therapy offers a potential solution by enabling localized, signal-dependent production of therapeutic proteins.
Purpose of the Study:
- To develop and evaluate an inflammation-inducible gene expression system for controlled recombinant protein production in vivo.
- To assess the feasibility of linking therapeutic protein expression to the intensity of inflammatory conditions.
Main Methods:
- A two-component gene expression construct was engineered, utilizing the murine complement factor 3 (C3) promoter to drive the expression of human immunodeficiency virus (HIV) transactivator of transcription (Tat).
- The Tat protein subsequently activated gene expression from an HIV promoter, controlling the production of a reporter protein (luciferase).
- This system was incorporated into a nonreplicating adenovirus vector (Ad.C3-tat/HIV-luc) and tested in a murine model under inflammatory stimuli.
Main Results:
- The Ad.C3-tat/HIV-luc construct successfully produced significant amounts of recombinant protein in vivo.
- Protein production was demonstrably responsive to two distinct inflammatory stimuli, indicating successful induction.
Conclusions:
- The developed inflammation-inducible gene expression system effectively regulates recombinant protein production in response to inflammatory signals.
- This gene therapy approach holds promise for a more balanced and targeted management of inflammatory diseases, potentially minimizing the risks associated with chronic immunosuppression.